Zhongnan Medical Journal Press

Home Results

A total of 8 result was found. Results that relate to Cost-effectiveness analysis

Cost-effectiveness analysis of abemaciclib plus fulvestrant in the second-line treatment for HR﹢/HER2﹣ advanced breast cancer

Published on Chinese Journal of Pharmacoepidemiology 2023,32(11):1259-1266.
7273 times 2048 times

Xi ZHAO Xi YAN Ning LI Chun-Xia HOU

Abemaciclib Fulvestrant Hormone receptor-positive breast cancer Markov model Cost-effectiveness analysis
Details
Cost-effectiveness analysis of enzalutamide in the treatment of metastatic prostate cancer

Published on Chinese Journal of Pharmacoepidemiology 2024,33(3):269-276.
9664 times 2362 times

YANG Lei WANG Fengling HUANG Ling LI Yan ZHENG Hanrui ZHENG Lingli CHEN Li

Enzalutamide Metastatic prostate cancer Markov model Cost-effectiveness analysis
Details
Research progress of equity-informative health economic evaluation

Published on Chinese Journal of Pharmacoepidemiology 2024,33(8):929-937.
14359 times 2531 times

FANG Nan HE Xiaoning WU Jing

Economic evaluation Equity Equity-based weighting Distributional cost-effectiveness Extended cost-effectiveness analysis
Details
Economic evaluation of multi-station drug dispensing robots for intravenous infusion preparation

Published on Chinese Journal of Pharmacoepidemiology 2024,33(12):1375-1381.
17904 times 1721 times

SUN Zhihong ZHAO Shaoliang ZHOU Furong LIU Feiyu WANG Pengcheng ZOU Shaohua GUO Chenyu

Multi-station dispensing robot Pharmacy intravenous admixture services Dispensing efficiency Cost-effectiveness analysis Economic evaluation
Details
Pharmacoeconomic evaluation of ribociclib plus fulvestrant in second-line treatment of HR+/HER2- advanced breast cancer for postmenopausal women

Published on Chinese Journal of Pharmacoepidemiology 2025,34(6):612-620.
10229 times 1622 times

JIA Caifeng WANG Jie ZHANG Sen WANG Meiqi LI Sainan WANG Mingxia

Ribociclib Fulvestrant Advanced breast cancer Postmenopausal Pharmacoeconomic evaluation Cost-effectiveness analysis
Details
Evaluation of the pharmacoeconomics of recombinant human thrombopoietin for the treatment of cancer therapy-induced thrombocytopenia

Published on Chinese Journal of Pharmacoepidemiology 2026,35(4):371-378.
2017 times 516 times

LIANG Hai XIA Runan CHEN Huijuan JIANG Mengyu LI Fanqin YANG Miao MA Jinghe

Recombinant human thrombopoietin Interleukin-11 Cancer Thrombocytopenia Decision tree Cost-effectiveness analysis
Details
Cost-effectiveness analysis of fondaparinux compared with low molecular-weight heparin in the treatment of recurrent spontaneous abortion

Published on Chinese Journal of Pharmacoepidemiology 2026,35(3):281-287.
1921 times 487 times

ZHU Yurong LI Lanlan ZHANG Rui DAI Wei YANG Weihu

Recurrent spontaneous abortion Fondaparinux Low molecular-weight heparin Cost-effectiveness analysis
Details
Cost-effectiveness analysis of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment for progressed EGFR-mutant non-small-cell lung cancer

Published on Chinese Journal of Pharmacoepidemiology 2026,35(5):553-562.
321 times 59 times

JIN Lijun ZHANG Lele HAN Lu LYU Zhenye

Sacituzumab tirumotecan Non-small cell lung cancer EGFR mutation Quality adiusted life year Incremental Cost-effectiveness ratio Cost-effectiveness analysis Scenaio analysis
Details